Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25) | Synapse
April 27, 2026JNCI Journal of the National Cancer Institute0 citationsOpen Access
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
To evaluate the impact of maintenance olaparib combined with bevacizumab on health-related quality of life in patients with advanced ovarian cancer.
Clinical trial NCT02477644 assessing newly diagnosed advanced ovarian cancer patients.
Measured global health-related quality of life (HRQoL) across populations.
Evaluated HRQoL in both overall population and in HRD-positive subgroup.
No clinically meaningful detrimental effect on global HRQoL observed overall.
HRQoL in the HRD-positive subgroup also showed no significant decline.
Abstract
Adding maintenance olaparib to bevacizumab showed no clinically meaningful detrimental effect on global HRQoL either overall or in the HRD-positive subgroup. ClinicalTrials.gov ID: NCT02477644.